# Activity & Safety Study of KX2-391 Ointment in Participants With Actinic Keratosis on the Face or Scalp

> **NCT02838628** · PHASE2 · COMPLETED · sponsor: **Almirall, S.A.** · enrollment: 168 (actual)

## Conditions studied

- Actinic Keratosis

## Interventions

- **DRUG:** 50 mg of KX2-391 Ointment 1%
- **DRUG:** 50 mg of KX2-391 Ointment 1%

## Key facts

- **NCT ID:** NCT02838628
- **Lead sponsor:** Almirall, S.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-04-11
- **Primary completion:** 2017-01-11
- **Final completion:** 2017-12-22
- **Target enrollment:** 168 (ACTUAL)
- **Last updated:** 2021-04-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02838628

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02838628, "Activity & Safety Study of KX2-391 Ointment in Participants With Actinic Keratosis on the Face or Scalp". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02838628. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*